Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far. 

 

Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic.&nbsp;It underscores the challenges facing its new chief executive Mike Doustdar.&nbsp;He spoke to Bloomberg's Guy Johnson about the experience so far.&nbsp;
&nbsp;

Listen for top interviews from Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment.

Listen for top interviews from Bloomberg News. Hear conversations with the biggest names in finance, politics and entertainment.

Listen to top interviews from Bloomberg News.

Bloomberg Talks

Novo Nordisk CEO Mike Doustdar Talks Drug Sales 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/2d7de441-899b-4fa7-9e22-b38c00a0570f/transcript